Decoy Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Decoy Therapeutics Inc. (DCOY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $349.97 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2019-03-06
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $349.97K, a 13329.55% increase from fiscal 2017.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $2.61K, a 95.95% decline from fiscal 2016.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $64.30K, a 56.96% decline from fiscal 2015.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $149.39K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 10 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|
| 2018-12-31 | $349.97K 10-K · filed 2019-03-06 | |
| 2017-12-31 | $2.61K 10-K · filed 2019-03-06 | |
| 2016-12-31 | $64.30K 10-K · filed 2019-03-06 | |
| 2015-12-31 | $149.39K 10-K · filed 2018-03-07 | |
| 2014-12-31 | $51.72K 10-K · filed 2017-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |